Adebrelimab

Cat. No.: HY-P99422

CAS No.: 2247114-85-6

Target: PD-1/PD-L1; Apoptosis

Pathway: Immunology/Inflammation; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC)[1][2].

In Vitro

Adebrelimab (SHR-1316; 0.06- 1mg/mL; 48 hours) inhibits effects on the cell proliferation, migration, invasion of SK-BR-3 and AU565 cells[1].

Adebrelimab (SHR-1316; 0.1-1mg/mL; 48 hours) downregulateds the expression of PD-L1, p-PI3K, p-AKT and upregulates the expression FOXO1[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	SK-BR-3 and AU565 cells
Concentration:	0.06 mg/mL, 0.13 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL
Incubation Time:	48 hours
Result:	The viability of SK-BR-3 and AU565 cells decreased gradually.

Apoptosis Analysis[1]

Cell Line:	SK-BR-3 and AU565 cells
Concentration:	0.1 mg/mL, 1 mg/mL
Incubation Time:	48 hours
Result:	Promoted cell apoptosis.

Cell Migration Assay [1]

Cell Line:	SK-BR-3 and AU565 cells
Concentration:	0.1 mg/mL, 1 mg/mL
Incubation Time:	48 hours

Result:	Decreased the migration rate of SK-BR -3 and AU565 cells.

Western Blot Analysis[1]

Cell Line:	SK-BR-3 and AU565 cells
Concentration:	0.1 mg/mL, 1 mg/mL
Incubation Time:	48 hours
Result:	Downregulated the expression of PD-L1, p-PI3K, p-AKT and upregulated the expression FOXO1.

In Vivo

Adebrelimab (SHR-1316; 200 μg; three times a week; for 21 days) shows inhibition effects on tumor growth[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Pathogen free (SPF) BALB/c nude female mice (aged 5-6 weeks) injected with SK-BR-3 cells [1]
Dosage:	200 μg
Administration:	Three times a week; for 21 days
Result:	Significantly inhibited tumor growth.

REFERENCES

[1]. Zhiwei Liu, et al. The Synergistic Effects of Pyrotinib and SHR-1316 on HER2-positve breast cancer. Research Square. May 19th, 2022.

[2]. Wanpu Yan, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial. J Thorac Oncol. 2022 Sep 30;S1556-0864(22)01822-6.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA